CCEL — Cryo-Cell International Balance Sheet
0.000.00%
- $45.42m
- $50.39m
- $31.99m
- 89
- 68
- 40
- 72
Annual balance sheet for Cryo-Cell International, fiscal year end - November 30th, USD millions except per share, conversion factor applied.
2020 November 30th | 2021 November 30th | 2022 November 30th | 2023 November 30th | 2024 November 30th | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 10.4 | 8.34 | 1.72 | 0.98 | 3.5 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 6.32 | 5.25 | 6.04 | 6.58 | 7.31 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 18.6 | 15.8 | 9.61 | 9.45 | 12.6 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 1.94 | 4.15 | 14.2 | 22 | 22.7 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 46.2 | 60.7 | 64.9 | 61.2 | 64.7 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 16.4 | 21.1 | 19.5 | 20.9 | 21.6 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 48.9 | 56.5 | 66.4 | 72.3 | 77.9 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Total Equity | -2.67 | 4.18 | -1.52 | -11 | -13.2 |
Total Liabilities & Shareholders' Equity | 46.2 | 60.7 | 64.9 | 61.2 | 64.7 |
Total Common Shares Outstanding |